Glaucoma Clinical Study Presented at Summer AECOS

Glaucoma Clinical Study
Presented at Summer AECOS

Presented by Steven R. Sarkisian, Jr., MD, founder of Oklahoma Eye Surgeons and a leader in glaucoma surgical innovation.

Highlighting Innovation at the AECOS Summer Symposium

At the recent AECOS Summer Symposium, Steven R. Sarkisian, Jr., MD—founder of Oklahoma Eye Surgeons and a recognized leader in glaucoma surgical innovation—took the stage to present real-world glaucoma case studies from his own clinical practice.

During his presentation, Dr. Sarkisian spotlighted a multicenter clinical trial focused on compounded combination glaucoma medications.

Key Findings from the Multicenter Clinical Study

The featured study, titled “Prospective Multicenter Trial of a Compounded Fixed Combination of Timolol Maleate 0.5%, Brimonidine Tartrate 0.2%, Dorzolamide Hydrochloride 2%, Latanoprost 0.005% for Glaucoma,” provides prospective, double-blinded data on multi-active topical solutions.

Conducted in the U.S., the study was authored by a team of leading specialists:

Nathan M. Radcliffe, MD
Damien F. Goldberg, MD
Lauren Seo, BA

Streamlining Combination Therapy for Patients

Glaucoma care is complex. OSRX AutoRefill offers simple solutions through:

Quality, compounded medications for $27 or less for patients
Reliable direct-to-patient delivery every month — promoting patient adherence
Fewer refill-related calls— more time for patient care
No prior authorizations or insurance needed

With a streamlined prescribing process and reliable direct-to-patient delivery, this approach supports both clinicians and patients in maintaining simple, quality care.

See the study highlights

*Professional Disclosure: Drs. Sarkisian and Goldberg serve on the Medical Advisory Board for Ocular Science® (an affiliate of OSRX) and have a financial interest in the company.

OSRX compounded glaucoma medications carry serious risks, including burning and stinging upon instillation, allergic conjunctivitis, and bitter taste. View potential adverse events and contraindications at: https://osrxpharmaceuticals.com/osrx-apiaecontraindication. For professional use only. OSRX specializes in customizing compounded medications to meet unique patient needs. Compounded drugs are not FDAapproved, which means they have not undergone FDA premarket review for safety, effectiveness, or quality.